|
1
|
Aguayo-González A and Tuna-Aguilar EJ:
Actual aspects of chronic myeloid leukemia. Rev Invest Clin.
64:192–198. 2012.PubMed/NCBI
|
|
2
|
Sawyers CL and Druker B: Tyrosine kinase
inhibitors in chronic myeloid leukemia. Cancer J Sci Am. 5:63–69.
1999.PubMed/NCBI
|
|
3
|
Faderl S, Talpaz M, Estrov Z, O'Brien S,
Kurzrock R and Kantarjian HM: The biology of chronic myeloid
leukemia. N Engl J Med. 341:164–172. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Quintás-Cardama A and Cortes JE: Chronic
myeloid leukemia: diagnosis and treatment. Mayo Clin Proc.
81:973–988. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
La Starza R, Testoni N, Lafage-Pochitaloff
M, et al: Complex variant Philadelphia translocations involving the
short arm of chromosome 6 in chronic myeloid leukemia.
Haematologica. 87:143–147. 2002.PubMed/NCBI
|
|
6
|
Al-Achkar W, Wafa A, Ikhtiar A and Liehr
T: Three-way Philadelphia translocation t(9;10;22)(q34;p11.2;q11.2)
as a secondary abnormality in an imatinib mesylate-resistant
chronic myeloid leukemia patient. Oncol Lett. 5:1656–1658.
2013.PubMed/NCBI
|
|
7
|
Sessarego M, Fugazza G, Bruzzone R,
Ballestrero A, Miglino M and Bacigalupo A: Complex chromosome
rearrangements may locate the bcr/abl fusion gene sites other than
22q11. Haematologica. 85:35–39. 2000.PubMed/NCBI
|
|
8
|
Cohen MH, Dagher R, Griebel DJ, et al:
U.S. Food and Drug Administration drug approval summaries: imatinib
mesylate, mesna tablets, and zoledronic acid. Oncologist.
7:393–400. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cowan-Jacob SW, Fendrich G, Floersheimer
A, et al: Structural biology contributions to the discovery of
drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D
Biol Crystallogr. 63:80–93. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
White D, Saunders V, Grigg A, et al:
Measurement of in vivo BCR-ABL kinase inhibition to monitor
imatinib-induced target blockade and predict response in chronic
myeloid leukemia. J Clin Oncol. 25:4445–4451. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shaffer L, Slovak M and Cambell L: I SCN
(2009): An International System for Human Cytogenetic Nomenclature.
S. Karger; Basel: pp. 40–44. 2009
|
|
12
|
Brothman AR, Persons DL and Shaffer LG:
Nomenclature evolution: Changes in the ISCN from the 2005 to the
2009 edition. Cytogenet Genome Res. 127:1–4. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Babicka L, Zemanova Z, Pavlistova L, et
al: Complex chromosomal rearrangements in patients with chronic
myeloid leukemia. Cancer Genet Cytogenet. 168:22–29. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aguayo A, Garcia-Alvarez E,
Cazares-Ordonez Y, Crespo-Solis E, Martinez-Baños D,
Guadarrama-Beltran E, Cervera-Ceballos EE and Lopez-Karpovitch X:
Chronic myeloid leukemia: a clinicoepidemiologic and therapeutic
description of a single institution in Mexico City. Clinical
Leukemia. 2:261–266. 2008. View Article : Google Scholar
|
|
15
|
Mkrtchyan H, Ghazaryan S, Avetisyan G,
Hovhannisyan A, Muradyan L, Daghbashyan S, Karst C, Gross M,
Hinreiner S, Aroutiounian R and Liehr T: Novel complex t(V;9;22)
rearrangements in three cases with chronic myeloid leukemia and a
rare translocation in a case with classical Philadelphia
chromosome. Oncol Rep. 20:99–104. 2008.PubMed/NCBI
|
|
16
|
Cortes J, Giles F, O'Brien S, et al:
Result of high-dose imatinib mesylate in patients with Philadelphia
chromosome-positive chronic myeloid leukemia after failure of
interferon-alpha. Blood. 102:83–86. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baccarani M, Saglio G, Goldman J, et al:
Evolving concepts in the management of chronic myeloid leukemia:
recommendations from an expert panel on behalf of the European
Leukemia Net. Blood. 108:1809–1820. 2006. View Article : Google Scholar : PubMed/NCBI
|
